Pivotal Study to Evaluate Efficacy and Safety of SP5M001 Inj. as Compared to Synovian Inj. in Patients With Mild to Moderate Knee Osteoarthritis

NCT ID: NCT06307847

Last Updated: 2024-03-13

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE3
• Total Enrollment: 223 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2021-04-14
• Study Completion Date: 2022-10-25

Brief Summary

This is a randomized, double-blind, multicenter, non-inferiority, pivotal clinical trial to assess the efficacy and safety of the novel hexamethylenediamine (HMDA) cross-linked hyaluronate intra-articular injection (SP5M001) compared with an active comparator, the 1,4-butanediol diglycidyl ether (BDDE) cross-linked hyaluronate (Synovian) in patients with knee osteoarthritis.

Conditions

Osteoarthritis Thumb

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

SP5M001 inj

SP5M001 inj 5 ml pre-filled syringe into Knee joint cavity of osteoarthritis patients

Group Type: EXPERIMENTAL

SP5M001 inj

Intervention Type: DRUG

pre-filled syringe

Synovian inj

Synovian inj 3 ml pre-filled syringe into Knee joint cavity of osteoarthritis patients

Group Type: ACTIVE_COMPARATOR

Synovian inj

Intervention Type: DRUG

pre-filled syringe

Interventions

SP5M001 inj

pre-filled syringe

Intervention Type: DRUG

Synovian inj

pre-filled syringe

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Adult males and females aged 40 years or older as of the date of written consent

2. Subject with knee osteoarthritis whose X-ray test results within 6 months from the screening or at the screening visit correspond to grades I - III of the Kellgren & Lawrence scale

3. Subject diagnosed with unilateral or bilateral knee osteoarthritis according to the clinical diagnostic criteria of the American College of Rheumatology (ACR) at screening who have knee joint pain and meet three or more of the following conditions

• Over 50 years of age

• Less than 30 minutes of morning stiffness ③ Crepitus on active motion ④ Bony tenderness ⑤ Bony enlargement ⑥ No palpable warmth of synovium

4. Weight bearing pain (WBP) of at least one of both knee joints on 100 mm-VAS ≥ 40 mm when measured at screening and baseline [However, if both sides have symptoms, the knee joint with the higher WBP becomes the joint for evaluation, and the selected joint cannot be changed during the study period.]

5. Walk without relying on a walking aid such as a walker or cane (patients who have been using a walking aid every day since 6 months prior to the screening visit can use the walking aid, and must use the walking aid in the same way throughout the study period.)

6. Ability to fully understand and complete the safety and efficacy measurement questionnaire

7. Voluntary decision for participation and provision of written consent to comply with the precautions after hearing and fully understanding the detailed explanation of the purpose, method, and effects of this study

Exclusion Criteria

1. Body mass index (BMI) ≥ 35 kg/m2 at screening

2. Hip osteoarthritis or osteoarthritis of another joint that is severe enough to preclude evaluation of knee osteoarthritis at the time of screening

3. Having the following diseases that may affect the efficacy and safety evaluation but not being limited to the following

• Septic arthritis, rheumatoid arthritis, gout, recurrent pseudogout arthritis, trauma that may damage joint cartilage, congenital abnormalities, calcium deposition disease, diabetes, ochronosis, hemochromatosis, acromegaly, Wilson's disease, primary osteochondrosis, genetic diseases (e.g., hyperkinesis), secondary osteoarthritis caused by collagen gene abnormalities, etc.
• Sudek's atrophy or severe painful diseases such as Paget's disease

4. Infection or skin disease in the joint area that is unsuitable for injection at the time of screening

• 5) Active or suspected knee joint infection at the time of screening
• 6) Complete loss of the Patello-femoral joint space
• 7) Received the following treatments within 14 days of the screening visit (except those who have passed a 14-day wash-out) or scheduled to be administered during the study period
• Taking medicines containing ingredients such as glucosamine, chondroitin sulfate, and diacerhein
• Taking herbal medicines and herbal medicines for osteoarthritis
• Taking anti-inflammatory painkillers, non-steroidal anti-inflammatory drugs (NSAIDs, prescription/non-prescription drugs), etc. (administration of acetaminophen allowed if passing a 3 day wash-out)
• Taking oral steroids
• Hospital physical therapy or oriental medicine treatment (cupping, acupuncture, moxibustion, etc.)

8) Intra-articular injection, such as intra-articular corticosteroid, at the injection site within 6 months from the time of screening 9) Systemic use of steroids within 3 months from the time of screening (including inhalants, however, topical application is permitted only on the upper body) 10) Hyaluronic acid intra-articular injection administered to the injection site within 6 months from the time of screening 11) Surgical operations such as knee joint replacement, including arthroscopic surgery, at the administration site within 6 months from the time of screening; or expecting surgery within 10 months 12) History of artificial joint surgery on the knee joint subject for evaluation 13) Knee joint subject for evaluation diagnosed as Kellgren Lawrence grade 4 within 6 months from the time of screening 14) Moderate or severe joint effusion by Patella tap test at the screening visit 15) History of hypersensitivity to ingredients of the IP or active control drug 16) Antiplatelet agents (excluding aspirin of 300 mg/day or less), heparin, oral anticoagulants (coumarin anticoagulants, thrombin inhibitors, Factor Xa inhibitors, etc.), and thrombolytics must be used during the study 17) Clinically significant abnormalities in liver function (3 times or more than the upper limit of normal for ALT/AST) or abnormalities in renal function (3 times or more than the upper limit of normal for serum creatinine), or severe liver or renal disease at the discretion of the investigator which is judged to have an impact on the effectiveness and safety evaluation of the study

• Minimum Eligible Age: 40 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Shin Poong Pharmaceutical Co. Ltd.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Yeungnam University Medical Center

Daegu, , South Korea

Cheonam National University Hwasun Hospital

Hwasun, , South Korea

Gachon University Gil Medical Center

Incheon, , South Korea

Jeonbuk National University Hospital

Jeonju, , South Korea

Chungnam National University Hospital

Sejong, , South Korea

Seoul National University Bundang Hospital

Seongnam-si, , South Korea

Asan Medical Center

Seoul, , South Korea

Chung-ang University Hospital

Seoul, , South Korea

Kyung Hee University Hospital at Gangdong

Seoul, , South Korea

Kyunghee University Hospital

Seoul, , South Korea

Samsung Medical Center

Seoul, , South Korea

Seoul National University Hospital

Seoul, , South Korea

Soon Chun Hyang University Hospital Seoul

Seoul, , South Korea

The Catholic University of Korea, Seoul St. Mary's Hospital

Seoul, , South Korea

Countries

South Korea

References

Kim KI, In Y, Choi HS, Lee JH, Sim JA, Lee HJ, Moon YW, Shon OJ, Seon JK, Kim YM, Song SJ, Chang CB, Han HS. A Multicentre, Double-Blind, Randomised, Non-Inferiority Trial of a Novel Single-Injection Intra-Articular HMDA-Cross-Linked Hyaluronate Gel for Knee Osteoarthritis. J Clin Med. 2025 Jun 19;14(12):4384. doi: 10.3390/jcm14124384.

Reference Type: DERIVED

PMID: 40566128 (View on PubMed)

Other Identifiers

SP-HA-003

Identifier Type: -

Identifier Source: org_study_id